A small percentage of stage four breast cancer patients will qualify for the Palbociclib clinical trial, but doctors say it is a step in the right direction.
The Food and Drug Administration gave the Pfizer medication breakthrough status.
"Cancer cells mutate and get smarter and so when we make a move to stop them, they figure out a new pathway and a lot of clinical researchers are finding blockers of the second pathway," says Dr. Bill Fintel, oncologist with Blue Ridge Cancer Care. "There are exciting developments. It is not going to cure cancers, but all cures of cancers come by incremental growth and incremental steps. This looks like an important step."
To see if you qualify for the clinical trial through Blue Ridge Cancer Care, call (540) 982-0237.